EA200701221A1 - Режим применения кладрибина для лечения рассеянного склероза - Google Patents

Режим применения кладрибина для лечения рассеянного склероза

Info

Publication number
EA200701221A1
EA200701221A1 EA200701221A EA200701221A EA200701221A1 EA 200701221 A1 EA200701221 A1 EA 200701221A1 EA 200701221 A EA200701221 A EA 200701221A EA 200701221 A EA200701221 A EA 200701221A EA 200701221 A1 EA200701221 A1 EA 200701221A1
Authority
EA
Eurasian Patent Office
Prior art keywords
multiple sclerosis
treatment
kladribin
application regime
preparation
Prior art date
Application number
EA200701221A
Other languages
English (en)
Other versions
EA015799B1 (ru
Inventor
Джампьеро Де Лука
Original Assignee
Лаборатуар Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лаборатуар Сероно С.А. filed Critical Лаборатуар Сероно С.А.
Publication of EA200701221A1 publication Critical patent/EA200701221A1/ru
Publication of EA015799B1 publication Critical patent/EA015799B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описано применение кладрибина для получения фармацевтического состава для лечения рассеянного склероза, особенно рецидивирующего-ремиттирующего рассеянного склероза или раннего вторичного прогрессирующего рассеянного склероза, причем препарат предназначен для перорального введения и допустимы его повторные применения.
EA200701221A 2004-12-22 2005-12-20 Режим применения кладрибина для лечения рассеянного склероза EA015799B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
EA200701221A1 true EA200701221A1 (ru) 2008-02-28
EA015799B1 EA015799B1 (ru) 2011-12-30

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701221A EA015799B1 (ru) 2004-12-22 2005-12-20 Режим применения кладрибина для лечения рассеянного склероза

Country Status (24)

Country Link
US (2) US7713947B2 (ru)
EP (6) EP4070800A1 (ru)
JP (7) JP5795456B2 (ru)
KR (1) KR20070091662A (ru)
AR (1) AR052830A1 (ru)
AU (2) AU2005318190B2 (ru)
BR (1) BRPI0517132B8 (ru)
CA (2) CA2588966C (ru)
CY (3) CY1112614T1 (ru)
DK (2) DK2805723T3 (ru)
EA (1) EA015799B1 (ru)
ES (1) ES2921858T3 (ru)
FR (1) FR18C1008I2 (ru)
HR (1) HRP20120228T1 (ru)
HU (2) HUE059133T2 (ru)
IL (2) IL183930A0 (ru)
LT (2) LT3332789T (ru)
LU (1) LUC00064I2 (ru)
MX (1) MX2007007610A (ru)
NO (1) NO20073813L (ru)
PL (3) PL1827461T3 (ru)
SG (1) SG160391A1 (ru)
SI (2) SI3332789T1 (ru)
WO (1) WO2006067141A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
WO2019101960A1 (en) 2017-11-24 2019-05-31 Merck Patent Gmbh Cladribine regimen for use intreating progressive forms of multiple sclerosis
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
EP0801571B1 (en) 1994-12-22 2002-09-04 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP4757632B2 (ja) 2002-09-25 2011-08-24 ブリガム ヤング ユニバーシティー ２’−デオキシグアノシンから２−クロロ−２’−デオキシアデノシンを調製する方法
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
JP2006518725A (ja) * 2003-02-25 2006-08-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 脱髄疾患におけるリバビリンとインターフェロンベータの併用
BR122018068797B1 (pt) 2003-03-28 2021-04-27 Ares Trading S.A. Composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
CA2520522C (en) 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
JP2008524313A (ja) 2008-07-10
HRP20120228T1 (hr) 2012-04-30
LUC00064I2 (ru) 2018-03-28
EP2805723A1 (en) 2014-11-26
DK2805723T3 (da) 2018-01-29
LTPA2018503I1 (lt) 2018-03-12
EP2263678A3 (en) 2011-04-27
JP2016138128A (ja) 2016-08-04
DK3332789T3 (da) 2022-07-11
EP2275110A3 (en) 2011-04-27
FR18C1008I2 (fr) 2019-03-01
EP2263678A2 (en) 2010-12-22
EP3332789A1 (en) 2018-06-13
NO20073813L (no) 2007-09-21
JP6290962B2 (ja) 2018-03-07
EP2275110A2 (en) 2011-01-19
JP6430554B2 (ja) 2018-11-28
BRPI0517132B1 (pt) 2020-02-18
JP2020193206A (ja) 2020-12-03
CY1119790T1 (el) 2018-06-27
AU2011200768B2 (en) 2012-09-13
EP2263678B1 (en) 2014-06-11
CA3087419C (en) 2023-03-07
IL212421A0 (en) 2011-06-30
AU2005318190A1 (en) 2006-06-29
EA015799B1 (ru) 2011-12-30
IL212421A (en) 2014-01-30
EP2275110B1 (en) 2013-07-10
HUE059133T2 (hu) 2022-10-28
SI2805723T1 (en) 2018-02-28
EP4070800A1 (en) 2022-10-12
MX2007007610A (es) 2007-08-03
EP2805723B1 (en) 2018-01-17
EP1827461B1 (en) 2012-02-29
LUC00064I1 (ru) 2018-02-14
CA2588966C (en) 2020-07-21
JP2015180685A (ja) 2015-10-15
FR18C1008I1 (ru) 2018-03-30
EP1827461A1 (en) 2007-09-05
CY1112614T1 (el) 2016-02-10
CY2018006I1 (el) 2018-06-27
BRPI0517132B8 (pt) 2021-05-25
PL1827461T3 (pl) 2012-07-31
PL2805723T3 (pl) 2018-04-30
JP5795456B2 (ja) 2015-10-14
JP5908863B2 (ja) 2016-04-26
JP2017101061A (ja) 2017-06-08
US8377903B2 (en) 2013-02-19
US7713947B2 (en) 2010-05-11
CA2588966A1 (en) 2006-06-29
PL3332789T3 (pl) 2022-08-22
JP6092945B2 (ja) 2017-03-08
AR052830A1 (es) 2007-04-04
HUS1800009I1 (hu) 2018-05-02
CA3087419A1 (en) 2006-06-29
BRPI0517132A (pt) 2008-09-30
CY2018006I2 (el) 2018-06-27
WO2006067141A1 (en) 2006-06-29
KR20070091662A (ko) 2007-09-11
US20090081163A1 (en) 2009-03-26
AU2011200768A1 (en) 2011-03-17
LTC2805723I2 (lt) 2022-04-25
JP2018165271A (ja) 2018-10-25
SG160391A1 (en) 2010-04-29
JP2013216664A (ja) 2013-10-24
US20100203017A1 (en) 2010-08-12
AU2005318190B2 (en) 2010-11-25
SI3332789T1 (sl) 2022-08-31
EP3332789B1 (en) 2022-04-06
ES2921858T3 (es) 2022-09-01
LT3332789T (lt) 2022-07-25
IL183930A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
EA200701221A1 (ru) Режим применения кладрибина для лечения рассеянного склероза
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
EA200501586A1 (ru) Фармацевтические продукты
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
HK1107699A1 (en) Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
RS50523B (sr) Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
SI1827461T1 (sl) Kladribinski režim za zdravljenje multiple skleroze
ATE402703T1 (de) Tablette enthaltend efletirizin und pseudoephedrin
ATE314851T1 (de) Synergistische wechselwirkung von abacavir und alovudin
ITTO20040343A1 (it) Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo
AR044360A1 (es) Composiciones farmaceuticas que comprenden un analeptico y otros farmacos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

ND4A Extension of term of a eurasian patent